Trial Profile
Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 06 Jun 2023 Results of application of AI-powered spatial TIL analyzer, Lunit SCOPE IO, to tumor specimens of the patients included in the trial to assess the impact of spatial TIL density and inflamed immune phenotype (IIP) on immunotherapy responses , presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 19 Mar 2023 Planned End Date changed from 1 Dec 2022 to 1 Oct 2023.
- 19 Mar 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Oct 2023.